Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene/Novartis d-methylphenidate

Executive Summary

Novartis will fund all further product development and marketing expenses in the approval process under a worldwide license (excluding Canada) to market the chirally pure version of Ritalin (methylphenidate). Celgene expects to file the d-methylphenidate NDA for treatment of attention deficit disorder during the third quarter. The chiral product will carry a Ritalin family name. Celgene's previous name for the d-methylphenidate product, Attenade, will no longer be used

You may also be interested in...



Novartis Focalin Price Similar To Ritalin; ADHD Drug Clears FDA Nov. 13

Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel